---
title: "\"Big Banks\" JP Morgan: MicroPort Medbot's overseas expansion accelerates, maintains \"Overweight\" rating"
description: "JP Morgan released a report stating that MicroPort Medbot's core product \"TUMAI\" has surpassed 200 orders, demonstrating strong market demand. The product's coverage has expanded to over 50 countries,"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275865856.md"
published_at: "2026-02-13T07:04:46.000Z"
---

# "Big Banks" JP Morgan: MicroPort Medbot's overseas expansion accelerates, maintains "Overweight" rating

> JP Morgan released a report stating that MicroPort Medbot's core product "TUMAI" has surpassed 200 orders, demonstrating strong market demand. The product's coverage has expanded to over 50 countries, particularly performing well in emerging markets such as India and Brazil. JP Morgan maintains an "Overweight" rating on MicroPort Medbot with a target price of 41 yuan, believing it will benefit from the trend of import substitution

JP Morgan published a research report stating that MicroPort Medbot-B (02252.HK) has accumulated over 200 orders for its core product "TUMAI," meaning approximately 20 new orders have been added since late January 2026, continuing the strong momentum from October 2025 to January 2026, and alleviating some market concerns about its sustainability. The coverage has expanded to over 50 countries and regions (more than 40 by the end of December 2025), with 12 markets ordering more than five units, primarily led by emerging markets such as India and Brazil, while developed markets like Spain and Australia have also achieved accelerated breakthroughs.

MicroPort Medbot primarily provides surgical robots for minimally invasive surgery, with "TUMAI" and "HONGHU" being its core products in the fields of laparoscopic and orthopedic surgery, respectively. "TUMAI" is the first clinically validated Chinese-made laparoscopic surgical robot that is comparable in efficacy to the Da Vinci Surgical System, which is currently the leading product of Intuitive Surgical in China and globally. The firm believes this achievement establishes MicroPort Medbot as a leading domestic enterprise in China, allowing it to benefit from the trend of import substitution. JP Morgan has given MicroPort Medbot a "Buy" rating, with a target price of 41 yuan

### Related Stocks

- [159898.CN - China Merchants CSI All Share Medical Apparatus and Instruments ETF](https://longbridge.com/en/quote/159898.CN.md)
- [02252.HK - MircroPort Medbot-B](https://longbridge.com/en/quote/02252.HK.md)
- [562600.CN - ChinaAMC CSI All Share Health Care Devices ETF](https://longbridge.com/en/quote/562600.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Finland's Modulight Q4 revenue rises, helped by growth in PPT business | Finland's Modulight reported a 21% year-over-year increase in Q4 revenue, reaching EUR 1.74 million, with an EBITDA of E | [Link](https://longbridge.com/en/news/276428080.md) |
| Elon Musk’s Neuralink sparks BCI race in China | Neuralink, founded by Elon Musk, is driving a surge in brain-computer interface (BCI) development in China, with startup | [Link](https://longbridge.com/en/news/276460367.md) |
| 02:32 ETSobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030 | Sobi® (STO: SOBI) hosted its Capital Markets Day, announcing a strategy to achieve SEK 55bn in revenue by 2030, driven b | [Link](https://longbridge.com/en/news/276205979.md) |
| Sulaiman Alhabib FY Profit 2,401.47 Mln Riyals | Dr Sulaiman Al Habib Medical Services Group Company SJSC :SULAIMAN ALHABIB FY NET PROFIT 2,401.47 MILLION RIYALSSULAIMAN | [Link](https://longbridge.com/en/news/275995976.md) |
| REVIEW-Olympics-Bobsleigh-Germany claim all the team golds again but just miss Monobob | Germany's bobsledders achieved a remarkable feat by sweeping all three team golds for the third consecutive Olympics, na | [Link](https://longbridge.com/en/news/276536453.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.